Resverlogix Corp.OTCPK - Current
Thu, Sep. 15, 6:25 AM
Nov. 11, 2015, 12:03 PM
- Resverlogix (OTCPK:RVXCF) announces that the first patient has been dosed in its Phase 3 clinical trial, BETonMACE, assessing lead product candidate apabetalone (RVX-208) in high-risk patients with coronary artery disease (CAD) and type 2 diabetes. The primary endpoint is the effect of apabetalone on time to first occurrence of Major Cardiovascular Events (MACE) in the targeted population. MACE is a single composite endpoint that includes cardiovascular death or non-fatal myocardial infarction (heart attack) or stroke. All study participants will remain on high-dose statin therapy [Lipitor (atorvastatin) or Crestor (rosuvastatin)] with the test group receiving 200 mg/day of apabetalone (two 100 mg capsules per day).
- According to clinicaltrials.gov, the estimated final data collection date for the primary endpoint is September 2018. The estimated study completion date is October 2018.
- Apabetalone works via an epigenetic mechanism called BET (bromodomain and extra-terminal) inhibition which regulates disease-causing genes. It specifically inhibits the second bromodomain (BD2) within the BET protein called BRD4, thereby producing a potential treatment benefit in patients with CV disease, diabetes, chronic kidney disease, Alzheimer's and other conditions.
Jul. 8, 2015, 8:26 AM
- Calgary, Canada-based Resverlogix (OTCPK:RVXCF) secures a license agreement and definitive stock purchase agreement with China's Shenzhen Hepalink Pharmaceutical Co.
- The license agreement covers RVX-208, the company's investigational atherosclerotic plaque reducer. Resverlogix will be eligible to receive sales-based milestones of $5M - 90M if sales targets in the territories (China, Hong Kong, Taiwan and Macau) are met (500M RMB - 10B RMB) ($80.5M - 1.6B). It will also receive a royalty of 6% of net sales of RVX-208. The agreement will be effective for 15 years after the first commercial sale or the expiry of the last-to-expire licensed patent, whichever is later. Hepalink will be responsible for all clinical and development costs.
- The stock purchase agreement specifies that Hepalink will establish a 12.63% stake in Resverlogix via the purchase of 13.27M units at CDN$2.67 per unit. Each unit consists of one share of common stock and 0.075358 of a warrant to purchase one common share at CDN$2.67.
- After the Hepalink deal is completed, another investor, Eastern Capital Limited, will buy 5.6M units at CDN$2.67 per unit.
Mar. 6, 2010, 1:35 PM